key: cord-0058135-wh2mycqk authors: Cassis, Joseph; Gaiser, Robert title: Complications of Blood Transfusion date: 2021-03-13 journal: Essentials of Blood Product Management in Anesthesia Practice DOI: 10.1007/978-3-030-59295-0_12 sha: 7f7c8640a2c4afd246f2c92138c76b065befb342 doc_id: 58135 cord_uid: wh2mycqk As any procedure in medicine, the transfusion of blood products to the patient involves benefits and risks. The benefits of increased oxygen carrying capacity with the ability to deliver oxygen to the tissue is clear in the setting of severe hemorrhage. The risks are not as clear. While patients are mainly concerned with infectious risks, there are other risks that must be considered by the provider. Transfusion-related acute lung injury (TRALI) is an acute lung injury that occurs within 6 hours of blood transfusion; the entity was first described in 1951 [1] . The actual syndrome and its link to the administration of blood products did not occur until 1983. In a case series of 3130 consecutive blood transfusions, five patients developed respiratory distress in close association to the transfusion [2] . The lung injury was linked to the transfusion with term TRALI being used. TRALI occurs in both women and men and occurs in patients of any age, except neonates. The reason for the concern with TRALI is the significant morbidity and mortality. Survival from TRALI is estimated at 50%. All plasma-containing blood and blood components have been implicated in the development of TRALI. A common theme to the cases of TRALI is the receipt of blood products 6 hours prior to the development of pulmonary symptoms. Other symptoms that also may occur include fever and hypotension. A consensus panel was convened in 2004 to establish the criteria for the diagnosis of TRALI [3] . TRALI was defined as a new acute lung injury that occurred during or within 6 hours of a completed transfusion that was not related to another cause for the lung injury. While the diagnosis requires the administration of the blood products within 6 hours, the overwhelming majority of patients will have the onset of symptoms within 1-2 hours following the transfusion. The diagnosis was to be based upon clinical symptoms combined with a radiographic diagnosis. The diagnostic criteria for TRALI are outlined in Table 12 .1. The chest x-ray should show bilateral infiltrates that may be patchy or diffuse suggestive of alveolar or interstitial disease [4] . Possible TRALI is a diagnosis used when it is difficult to determine whether the actual etiology of the lung injury is TRALI or another cause of the acute lung injury [5] . Sometimes it is difficult to determine whether the lung injury is from the blood transfusion. In patients meeting the diagnosis of TRALI but with another reason to explain the acute lung injury, the alternative diagnosis of "possible TRALI" is used. Possible TRALI refers to transfusion-related lung injury in a patient with a preexisting lung injury prior to the transfusion. This term is not universally accepted, with many feeling that possible TRALI is simply ARDS or TRALI type II (TRALI in a patient with risk factor for ARDS) [6] . Postmortem tissue examination of patients with TRALI demonstrates pulmonary edema, diffuse alveolar damage, and granulocytes in the alveoli. The pulmonary vasculature contains neutrophil aggregates when examined postmortem. The major finding in patients with TRALI is increased pulmonary microvascular permeability with protein in the fluid. Patients with TRALI have chest x-rays that demonstrate bilateral infiltrates that suggest cardiac failure with no evidence for cardiac causes of the findings. The pathogenesis is poorly understood. The most common theory for TRALI is the two hit model in the transfused donor [1] . In this theory, a patient who had an increase in neutrophil responsiveness receives a stimulus from the transfusion itself. The possible risk factors (Table 12. 2) that may cause the first hit include chronic alcohol abuse, sepsis, mechanical ventilation, shock, surgery, smoking, inflammation, and fluid overload. The inflammatory proteins that are elevated in patients with TRALI include interleukin-6 and interleukin-8 as well as protein C-reactive protein. The second hit comes from the antibodies in the transfused blood products. In the two-hit model, a certain threshold from the initial insult must be present in a patient who receives a sufficient amount of volume and titer of antibody. If the amount of antibody is insufficient to initiate antibody-antigen activation, TRALI will not occur. In the critically ill patient, the neutrophils are primed and ready to be activated from the antibodies in the transfused blood, which leads to pulmonary edema. Approximately 80% of cases of TRALI are due to the presence of donor antibodies such as antihuman leukocyte or antihuman neutrophil antibodies. The implicated antibodies include cognate anti-HLA-Class II and anti-human neutrophil antigen (HNA)-positive antibodies. Antibodies are the second hit for TRALI. Antibodies to leukocyte antigen Class I or II or neutrophil antigen can be detected in the transfused blood of patients who develop TRALI. These antibodies in the donor product activate neutrophils in the recipient lung causing pulmonary damage and capillary leak. Donors have developed these antibodies when the immune system comes into contact with foreign HNA or HLA during pregnancy, transfusion, or transplantation [7] . The remaining 20% of cases of TRALI are related to biolipids of the blood products or components from aging blood. These microparticles occur in blood products and activate inflammatory mediators resulting in plasma leak within the lung. The microparticles may be generated from any cell, including platelets, red blood cells, and white blood cells. The exact mechanism for TRALI from this etiology is poorly understood [7] . Given the role of human leukocyte antigen antibodies in the development of TRALI, blood banks have moved toward the use of male-predominant plasma. Multiparous women have a high exposure to fetal HLA antigens and other granulocyte-borne antigens from the fetus. This knowledge has led to the practice of eliminating donor plasma from multiparous women or the screening of female donors for HLA antibodies. This practice was instituted in 2004. Prior to this change, the estimated incidence of TRALI was 1 in 5000 blood and blood components, 1 in 2000 plasmacontaining components, 1 in 7900 units of fresh frozen plasma, and 1 in 432 units of whole blood-derived platelets [8] . Since the introduction of male-predominant plasma, the incidence of TRALI has decreased. The University of Texas Health Science Center in Houston evaluated the incidence of TRALI as this center uses plasma in the setting of trauma, and the use is early and aggressive [9] . Over a 10-year period, a total of 714,757 units of blood products were transfused with seven cases of TRALI, giving an incidence of 1 in 102,000. As compared to the screening and discarding of blood based on the presence of antibodies, another approach is the use of pooled solvent-detergent-treated plasma instead of fresh frozen plasma. This treatment with solvent and detergent was done to inactivate lipid-enveloped viruses. This approach has been shown to be effective in eliminating the antibodies [10] . No specific treatment exists for TRALI. The provision of increased concentrations of oxygen is required in all, and mechanical ventilation is required in most [7] . Given the lung injury component of TRALI, it is recommended that lung protective strategies be used for ventilation. Also, these patients should not be treated with diuretics as fluid overload is not the precipitating factor. TRALI may be differentiated from transfusion-associated circulatory overload by obtaining a B-type natriuretic peptide level, which is elevated in overload. Other factors that differentiate TRALI from transfusion-associated circulatory overload include the elevated pulmonary capillary wedge pressure and the positive response to diuretics in overload. Given the two-hit theory, managing the patient's underlying risk factors as well as decreasing transfusion would decrease the incidence of TRALI. Transfusion-associated circulatory overload (TACO) is the most common type of transfusion-related pulmonary complication with an estimated incidence estimate of 1-8% (although some estimating it to be as high as 11%) [11] . TACO was first observed in the 1930s, but became recognized as a distinct clinical entity in the 1990s [12] . The incidence of TACO varies by study, with data from passive surveillance showing a very low incidence while studies with active surveillance reporting a higher incidence. This point highlights the general consensus that TACO is vastly underreported and lacks a clear, established defining set of criteria, as evidenced by the variation in the reported incidence among studies with active surveillance. Data from the Serious Hazards of Transfusion UK reporting system suggest [13] . TACO was more likely to occur with the transfusion of packed red blood cells (1/8000), as compared to plasma (1/15,000) or platelets (1/48,000) [14] . Various other studies have supported this relationship between volume transfused and TACO although the impact of the rate of transfusion on the incidence remains unknown. TACO is defined as acute cardiogenic pulmonary edema associated with volume overload occurring within 6 hours of receiving a blood transfusion [15] . This temporal relationship between transfusion of blood products and pulmonary edema is a key feature of TACO (as well as TRALI) distinguishing it from other forms of pulmonary edema. The pulmonary edema caused by TACO is thought to be due to increased hydrostatic pressure (i.e., cardiogenic pulmonary edema) as opposed to capillary leak (i.e., noncardiogenic pulmonary edema), the latter being associated with transfusion-related acute lung injury [16] . Although there is no consensus on standardized criteria for TACO, the Centers for Disease Control's Hemovigilance Module Surveillance Protocol proposed possible criteria for recognizing and diagnosing TACO (Table 12. 3) [17] . The CDC criteria state that a patient must have 3 or more of the following findings within 6 hours of cessation of transfusion: • Acute respiratory distress • Elevated brain natriuretic peptide(BNP) • Elevated CVP • Evidence of left heart failure • Evidence of positive fluid balance • Radiographic evidence of pulmonary edema Since TACO is a form of cardiogenic pulmonary edema related to the transfusion of blood products, understanding the pathophysiology of pulmonary edema will aide in the management of TACO. In the normal lung, fluid that is filtered out of circulation into the alveolar interstitial space does not enter the alveoli due to tight junctions that prevent passage; this fluid is removed via the lymphatics. The hydrostatic force for fluid filtration between the capillaries and alveoli microcirculation is roughly equal, with the osmotic pressure of the capillaries tipping the balance slightly in favor of capillary circulation [14] . In TACO, the hydrostatic pressure increases due to the rapid increase in circulatory volume resulting in an imbalance. There is an increase in fluid filtration (edema into the interstitial space), and the tight junctions of the epithelium are overcome allowing protein poor fluid to enter the alveolar space thus causing pulmonary edema. There are multiple risk factors for TACO, with age, cardiovascular dysfunction, and renal disease being the major risk factors. Although TACO can occur at any age, advanced age appears to be the greatest risk with most studies reporting the highest incidence in patients aged greater than 70 years. Patients with cardiovascular dysfunction also have a higher incidence of TACO. In particular, patients with CHF (especially NYHA Class 4), atrial fibrillation, a history of coronary artery disease, use of diuretics (and lack of use when there is evidence of TACO), and amiodarone all have a higher risk of developing TACO [16] . Chronic renal failure has also been shown to be a risk factor. Other risk factors include positive fluid status (fluids other than blood products can contribute to TACO), number of units transfused, type of product transfused (likely related to volume), rate of transfusion, preexisting pulmonary disease, female sex (although the evidence is not conclusive), patients of small stature, shock, anemia, and hospitalized patients (especially OR and ICU) [12, 14, 15] . Many of the risk factors lend credence to the hypothesis that TACO occurs when the body's ability to manage intravascular volume status is overwhelmed, especially when intravascular volume is increased by a large amount or at higher infusion rates. For example, the incidence of TACO correlates with the number of units of blood products transfused, and there is evidence that higher rates of infusion lead to higher incidence of TACO [12, 18] . Respiratory distress/worsening pulmonary status within 6 hours of receiving a blood transfusion is the principle manifestation of TACO. A patient's respirations, oxygen saturation, heart rate, temperature, blood pressure, and fluid balance should all be monitored closely during transfusion. Increasing oxygen requirement and decreasing oxygen saturation on pulse oximetry should warrant further investigation including a chest x-ray and physical exam. Consideration should be given to close monitoring for 24 hours after transfusion as multiple studies show clear evidence that active surveillance yields higher rates of recognition of TACO. Supplemental oxygen which is common in the OR and ICU can mask evidence for worsening pulmonary status, especially if the patient is intubated. Arterial blood gas monitoring measures the ratio of the partial pressure of oxygen to fractional inspired oxygen (PaO2/FiO2) which is used in ARDS and TRAILI and could prove useful in TACO. [14] Potential respiratory manifestations include the following: • Dyspnea • Tachypnea • Hypoxia • Pulmonary edema -CXR (possible enlarged cardiac silhouette, pleural effusions, enlarged vascular pedicle, distribution of edema is even/central • Orthopnea • Crackles In addition to respiratory status, patients should be monitored for cardiac dysfunction before, during, and after transfusion. Hypertension is sometimes, though not always, a distinguishing feature from the noncardiogenic pulmonary edema associated with TRALI. Physical examination of the patient may reveal jugular venous distention and peripheral edema. A patient's fluid balance should be determined before a transfusion is started as studies demonstrating overall positive volume status contribute to the development of TACO. Chart review, urine output, patient's weight, response to diuretics, and volume removed through dialysis can all be used to determine fluid balance. Bedside echocardiography may be utilized to determine cardiac function as well as volume status. B-type natriuretic peptide (BNP) and NT-pro-BNP have been studied as a way to diagnose TACO and differentiate it from TRALI to aide in clinical decision making. Unfortunately, the evidence is mixed as to whether or not BNP is an effective biomarker for distinguishing TACO from TRALI. The evidence is weaker for differentiating TACO from other forms of pulmonary edema [19] . The most significant problem with these biomarkers is the vast differen-tial and large number of factors that can explain elevations. Heart failure, renal dysfunction, age, gender, sepsis, and ACE inhibitors affect BNP and NT-pro-BNP levels. Management of TACO is essentially the same as managing patients with other causes of cardiogenic pulmonary edema. If TACO is suspected, the initial step in treatment is to stop the transfusion. Treatment should begin with supplemental oxygen and elevating the head of the bed to 30 degrees. Supplemental oxygen may be delivered via nasal canula; however, positive pressure may be required if the pulmonary edema is severe; BiPap or high flow nasal canula can be useful. Diuretic use has shown a significant decrease in not only the incidence of TACO but also the mortality when it occurs. In cases of severe renal failure, CRRT or hemodialysis is used to reduce volume overload. Reduction of afterload as tolerated by the patient may also prove useful in decreasing workload and increasing cardiac output. In the most severe cases, intubation, vasopressors, and inotropes are necessary. The understanding of the antigen/antibody cause for the blood group system was developed by Dr. Karl Landsteiner when he noted that mixing red blood cells with different plasma and different patterns of agglutination was obtained [20] . He termed the first pattern A and the second pattern B. There were other individuals who did not achieve any pattern of agglutination, which was termed C. The first two patterns led to the nomenclature of Type A and Type B; it was the lack of a pattern of agglutination that led to Type O. Furthermore, it was these observations that led Dr. Landsteiner to postulate that whichever ABO antigens are lacking on a red blood cell will result in the corresponding antibody. This theory has been termed Landsteiner's Law. The antigens for the ABO system are produced by various enzymes that add sugars to the oligosaccharide chain. The source of the antibodies is less clear; it may due to inherited antibodies or due to classical immune-mediated reactions. When ABO incompatible blood is administered, hemolysis may occur. For the transfusion of red blood cells, patients may receive group O red blood cells as these cells lack A and B antigens and are compatible with plasma. For plasma, all patients may receive AB plasma as these lack anti-A and anti-B antibodies. Of note, while ABO compatibility is vital for red blood cells to prevent a fatal acute hemolytic transfusion reaction, it is not vital and frequently not followed for plasma and platelets. Although plasma may contain anti-A or anti-B antibodies, the presence of A and B antigens on endothelial cells, dilution in the patient blood volume, and the presence of soluble A and B antigen in the plasma of secretors provide protection [21] . The presence of D antigen on the donor and recipient also must be considered. Antibody to the D antigen is not naturally occurring, requiring exposure to develop the antibody. Exposure to D+ red blood cells in a D-patient will result in the development of antibodies in 1 out of every 5 exposures. The formation of D antibodies is most important in women of childbearing age where the antibody may complicate the pregnancy. As such, men and women who are beyond childbearing typically receive D+ packed red blood cells, due to the shortage of D-blood. In fact, D-blood has become so low that many transfusion services provide D+ blood, even for women of childbearing age [21] . A febrile nonhemolytic transfusion reaction is defined as an increase in temperature of 1 degree Celsius above 37 degrees that occurs during or after the transfusion of blood products. This reaction is the most common during transfusion. The reaction may occur without the symptoms of chills, rigors, and rash or may occur with it. The most common blood product to produce a non-hemolytic transfusion reaction is platelets. Initially, it was felt that the reaction was due to the presence of white blood cells in the patient's plasma that reacted with the white cells in the blood product. This explanation mainly applies to red blood cells; platelets have a different explanation. The reaction is more likely to occur the older the platelets are. Within the stored platelets, there is the generation of cytokines during storage. These cytokines are responsible for the reaction [22] . The most important point when a patient develops a febrile response to a transfusion is to insure that it is not due to an acute hemolytic reaction or transfusion of a contaminated product. There is always the risk of administering the wrong blood product to the patient. While infectious disease transmission has decreased, mistransfusion remains a constant risk to the patient [23] . In an effort to prevent this error of incompatible blood products, an institution conducted a quality improvement project with the introduction of a cognitive aid. This cognitive aid was a simple card that was worn with the participants' badge, as demonstrated in Table 12 .4. Based upon a quiz, there was a marked improvement in ABO compatibility. Hemolytic transfusion reactions occur when the antibodies within the recipient react to the antigens on the red blood cell surface. These reacts are classified as acute or delayed. An acute reaction occurs during the transfusion, while a delayed reaction occurs within days or weeks of transfusion. The most common reason for a hemolytic transfusion reaction is misidentification of the patient or mislabeling the blood sample. When the IgM antibody binds to the antigen, the red cell membrane is destroyed resulting in the release of contents within the red blood cell into the circulation. The free hemoglobin damages the kidney, while the complement activation leads to disseminated intravascular coagulation [24] . Management includes stopping the transfusion and administering fluids, vasopressors, and blood products for the coagulopathy. A delayed reaction occurs from antibodies developed from a previous transfusion. These antibodies are not present in a detectable level at the time of the testing and appear days after the transfusion. Typical manifestations of a delayed reaction include anemia and jaundice. Transfusion-transmitted infection due to viral and bacterial contamination decreased dramatically with the transition to closed, sterile systems for collection and storage. John Elliott developed the first vacuum bottle for blood collection in 1940 [25, 26] . In addition, the testing of blood donations has further contributed to a dramatic reduction in transfusiontransmitted infections. By 1947, every unit of blood collected was tested for syphilis followed by hepatitis B in 1971, hepatitis C in 1990, and HIV-1 and 2 by 1992 [26] . Over time viral infections related to transfusion have seen a significant drop; transfusion-transmitted bacterial infection has not seen the same reduction over the last 30 years. According to studies from the US FDA, French Hemovigilance study, and the British SHOT study, the incidence for bacterial contamination/sepsis has not decreased (in fact, has not changed) to the same degree as viral infection [25] . Bacterial contamination is the most common cause of transfusion-transmitted infection, with an estimated overall prevalence of 0.2% [27, 28] . Bacterial infection is more common than viral or fungal infection. It is estimated that bacterial contamination is approximately 1 in 3000 units [29] . Transfusion-transmitted bacterial infections accounted for the most reports transfusion-related fatality, accounting for 20% of fatalities (second to ABO errors) [25, 30] . The actual incidence of transfusion-transmitted bacterial infection varies based on the study (Table 12 .5). This variation is likely due to differences in the processing and storage of blood products [30] . The FDA reports mortality from transfusion-related infections to range from 1 in 6,000,000 to 1 in 9,000,000 when examining all blood products together and 1 in 1,000,000 for platelets [30] . Though the incidence of bacterial contamination and transfusion-transmitted bacterial infections varies, the highest risk of contamination and infection occurs with platelets. This incidence is due to storage as platelets are stored at room temperature, allowing bacteria to grow that would otherwise remain dormant at lower levels with refrigeration. In countries where platelets are screened using BacT/ALERT culture system, the incidence of transfusion-transmitted bacterial infections is lower [31] . The detection of bacterial contamination in platelet samples is largely dependent on bacterial concentration as tests where resampling of a previously positive BacT/ALERT screenings has yielded negative results [32] . Unlike viruses, bacteria have the ability to multiply during storage making the duration of their storage another factor in the incidence of transfusion-related bacterial infection. One study found that the incidence of contamination and the bacterial levels measured were both significantly less for units transfused in under 4 days compared with units that were 5 days and older [33] . The infectious concern with the transfusion of red blood cells is primarily viral. The risk depends upon which testing is performed. Current testing of red blood cells includes Hepatitis B (antibody in 1987; nucleic acid in 2009), Hepatitis C (antibody in 1990; nucleic acid in 1999), Human Immunodeficiency Virus (antibody in 1985; nucleic acid in 2000), West Nile Virus, and Zika Virus [34] . The risk of viral infection occurs when a virus emerges in which testing does not occur, as happened with Zika Virus, which was added in 2016 [35] . Currently, blood is not tested for Hepatitis A, malaria, or new variants of Creutzfeld-Jacob disease prions. The transfusion of blood products has risk to the patient. There is always the risk of misidentification resulting in the administration of the wrong blood product. Even when the patient is properly cross-matched, there are infectious risks from both known and unknown agents. There is also the risk of transfusion-related acute lung injury and transfusion-associated circulatory overload. While the risks may be mitigated, they cannot be removed completely. These concerns help one understand the continually evolving transfusion thresholds and administer products only when truly indicated. Patients who received gram negative bacteria were at greatest risk of death Transfusion-transmitted bacterial infections accounted for the most reports transfusion related fatality after hemolytic reactions (>10% from [1985] [1986] [1987] [1988] [1989] [1990] [1991] [1992] [1993] [1994] [1995] [1996] [1997] [1998] [1999] Targeting transfusion-related acute lung injury: the journey from basic science to novel therapies Diagnostic and pathogenetic considerations in transfusion-related acute lung injury Toward an understanding of transfusion-related acute lung injury: statement of a consensus panel Consensus Panel TRALI. Proceedings of a consensus conference towards an understanding of TRALI Complications of allogeneic blood product administration, with emphasis on transfusion-related acutelung injury and transfusion-associated circulatory overload A consensus redefinition of transfusion-related acute lung injury Antibody-mediated transfusionrelated acute lung injury; from discovery to prevention Transfusion-related acute lung injury: definition and review The incidence of transfusion-related acute lung injury at a large,urban tertiary medical center: a decade's experience Perioperative transfusion-related acute lung injury A compendium of transfusion practice guidelines Transfusion associated circulatory overload (TACO) incidence and risk factors Clinical practice. Acute pulmonary edema National healthcare safety network biovigilance component hemovigilance module surveillance protocol. Accessed Risk factors and outcomes in transfusion-associated circulatory overload Serious Hazards of Transfusion (SHOT) haemovigilance and progress is improving transfusion safety Transfusion-associated circulatory overload and transfusion-related acute lung injury International Society of Blood Transfusion Working Party on Haemovigilance Transfusion-associated circulatory overload (TACO) Definition The accuracy of natriuretic peptides (BNP and NT-pro-BNP) in the differentiation between Transfusion Related Acute Lung Injury (TRALI) and Transfusion Related Circulatory Overload (TACO) in the critically ill Anti-A and anti-B: what are they and where do they come from? Immunologic risks of whole blood: ABO compatibility, D alloimmunization, and transfusion-related acute lung injury Pathophysiology of febrile nonhemolytic transfusion reactions Preventing mistransfusions: an evaluation of institutional knowledge and a response Hemolytic transfusion reactions Transfusion-transmitted bacterial infection: risks, sources, and interventions Highlights of transfusion medicine history Bacterial culture reduces but does not eliminate the risk of septic transfusion reactions to single donor platelets Determinants of transfusionassociated bacterial contamination: results of the French Bacthem Case-Control Study Bacterial contamination of platelet concentrates: incidence, significance, and prevention Transfusion-transmitted bacterial infection in the United States Storage medium of platelet transfusions and the risk of transfusion-transmitted bacterial infections Laboratory evaluation of the effectiveness of pathogen reduction procedures for bacteria A prospective microbiologic surveillance program to detect and prevent the transfusion of bacterially contaminated platelets Blood transfusion therapy Zika virus in the Americas -yet another arbovirus threat